A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth

NCT01662726 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
13
Enrollment
OTHER
Sponsor class

Stopped Recruitment challenging: lack of suitable pts; recruiting so soon after diagnosis; competing studies. Funding ended despite extensions to grant.

Conditions

Interventions

Sponsor

Imperial College London

Collaborators